China NMPA Drug Inspection - Ningxia Mingde Traditional Chinese Medicine Pieces Co., Ltd.

On July 14, 2020, the Gansu Provincial Drug Administration issued a formal correction to its previous Drug Quality Announcement (No. 28 of 2020), which was originally published on July 8, 2020. The primary entity identified in the notice is Ningxia Mingde Traditional Chinese Medicine Pieces Co., Ltd. The document serves to rectify data regarding non-compliant drug batches discovered during recent quality inspections. The original announcement incorrectly cited ten batches of drugs from seven different manufacturers as being non-compliant. The updated information clarifies that there are actually seven batches of non-compliant drugs originating from six manufacturers. These discrepancies involve violations of drug quality standards established under the regulatory framework of the National Medical Products Administration (NMPA). While the specific chemical or physical failures of the products were detailed in an attached list, the core issue involves the failure of these batches to meet established safety and efficacy benchmarks. The Gansu Provincial Drug Administration is responsible for oversight in this jurisdiction, ensuring that medicinal products adhere to strict quality control protocols. The required actions involve the official correction of public records to ensure accuracy in regulatory reporting. Such announcements typically mandate the withdrawal of the affected batches from the market and require the involved companies to implement corrective measures to prevent future quality deviations. This notice underscores the administration's commitment to transparency and rigorous monitoring of the pharmaceutical supply chain.